A multi-center, investigator-blinded, randomized, 12-month, parallel-group, non-inferiority study to compare the efficacy of 1.6 to 2.4 g Asacol (Rm) therapy QD versus divided dose (BID) in the maintenance of remission of ulcerative colitis.

Trial Profile

A multi-center, investigator-blinded, randomized, 12-month, parallel-group, non-inferiority study to compare the efficacy of 1.6 to 2.4 g Asacol (Rm) therapy QD versus divided dose (BID) in the maintenance of remission of ulcerative colitis.

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Apr 2013

At a glance

  • Drugs Mesalazine (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Acronyms QDIEM
  • Sponsors Procter & Gamble
  • Most Recent Events

    • 18 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Mar 2010 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 24 Mar 2010 Warner Chilcott added as trial sponsor and trial affiliate as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top